Abstract: The present invention is an aqueous pharmaceutical composition that includes an ionized therapeutic agent, an ionic component and guar gum. The guar gum is present in the composition a concentration sufficient to limit interactions between the ionized therapeutic agent and the ionic component thereby imparting stability to the composition. The composition is preferably at or near physiologic pH. The aqueous pharmaceutical composition has been found particularly useful as an aqueous ophthalmic, otic or nasal composition. The pharmaceutical composition, due to its characteristics, is particularly suitable as an ophthalmic composition.

Abstract: The present invention relates to viscosity stabilized ophthalmic formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a diol alcohol such as sorbitol and, optionally, a pharmaceutically acceptable divalent cation salt such as magnesium chloride.

Abstract: The present invention relates to artificial tear formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a cis-diol such as sorbitol that interferes with the cross-linking of galactomannan and borate. Optionally, the formulations are substantially free of divalent cations.

Abstract: A vehicle includes a first control configured to operate the vehicle from a first operator position facing a front of the vehicle and a second control configured to operate the vehicle from a second operator position facing a rear of the vehicle. The vehicle further includes a processor configured to monitor for an operator presence in the first operator position or the second operator position and receive a vehicle operating request, wherein the operator presence is monitored independent of receiving the vehicle operating request. The processor is further configured to enable either the first control or the second control and select a vehicle operating parameter associated with the vehicle operating request, wherein the vehicle operating parameter varies according to which control is enabled.

Abstract: The present invention relates to artificial tear formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a cis-diol such as sorbitol that interferes with the cross-linking of galactomannan and borate. Optionally, the formulations are substantially free of divalent cations.

Abstract: The present invention relates to processes for purifying guar comprising combining borate and guar in an aqueous solution and treating the aqueous solution with an organic solvent to induce precipitation of purified guar. Another embodiment of the present invention is directed to ophthalmic formulations comprising purified guar produced by the processes described.

Abstract: The present invention relates to artificial tear compositions and ophthalmic compositions suitable for drug delivery. In one embodiment of the present invention, the compositions comprise a galactomannan polymer such as guar or hydroxypropyl guar, hyaluronic acid, and a cis-diol such as sorbitol. In a preferred embodiment, the compositions also comprise a borate compound.

Abstract: The present invention relates to viscosity stabilized ophthalmic formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a diol alcohol such as sorbitol and, optionally, a pharmaceutically acceptable divalent cation salt such as magnesium chloride.

Abstract: The present invention relates to processes for purifying guar comprising combining borate and guar in an aqueous solution and treating the aqueous solution with an organic solvent to induce precipitation of purified guar. Another embodiment of the present invention is directed to ophthalmic formulations comprising purified guar produced by the processes described.

Abstract: A vehicle includes a first control configured to operate the vehicle from a first operator position facing a front of the vehicle and a second control configured to operate the vehicle from a second operator position facing a rear of the vehicle. The vehicle further includes a processor configured to monitor for an operator presence in the first operator position or the second operator position and receive a vehicle operating request, wherein the operator presence is monitored independent of receiving the vehicle operating request. The processor is further configured to enable either the first control or the second control and select a vehicle operating parameter associated with the vehicle operating request, wherein the vehicle operating parameter varies according to which control is enabled.

Abstract: The present invention relates to processes for purifying guar comprising combining borate and guar in an aqueous solution and treating the aqueous solution with an organic solvent to induce precipitation of purified guar. Another embodiment of the present invention is directed to ophthalmic formulations comprising purified guar produced by the processes described.

Abstract: The present invention relates to artificial tear formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a cis-diol such as sorbitol that interferes with the cross-linking of galactomannan and borate. Optionally, the formulations are substantially free of divalent cations.

Abstract: The use of poly(oxybutylene)-poly(oxyethylene)-poly(oxybutylene) block copolymers in pharmaceutical compositions useful, for modifying the surfaces of contact lenses and other medical devices is disclosed. The present invention is based in-part on a discovery that this class of compounds is particularly efficient in wetting hydrophobic surfaces, such as the surfaces of silicone hydrogel contact lenses and other types of ophthalmic lenses, but do not induce foaming when used in conjunction with a peroxide-based contact lens disinfection regimen. Such compounds may also be useful for cleaning purposes. The use of the compounds as surfactants in peroxide-based compositions for disinfecting contact lenses therefore represents a preferred embodiment of the present invention.

Abstract: The present invention relates to viscosity stabilized ophthalmic formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a diol alcohol such as sorbitol and, optionally, a pharmaceutically acceptable divalent cation salt such as magnesium chloride.

Abstract: A system for capturing regenerative energy includes a battery configured to provide power for a traction motor and other operations of a vehicle and a capacitor connected to the battery. An auxiliary motor is configured to operate as a generator during a regenerative energy operation. The system further includes a controller configured to direct the regenerative energy to the capacitor during the regenerative energy operation and discharge the capacitor to provide power to the traction motor or for the other operations of the vehicle.

Abstract: The present invention relates to ophthalmic solutions with antimicrobial activity. The solutions have an antimicrobial compound such as hydrogen peroxide and a boron compound. In one embodiment, the solutions contain a boron compound such as sodium borate that provides antimicrobial activity in addition to that of hydrogen peroxide, particularly during periods following disinfection and neutralization of such solutions. This additional activity reduces the likelihood of microbial growth in contact lens disinfection applications that neutralize hydrogen peroxide.

Abstract: The present invention relates to compositions comprising ethyleneoxide butyleneoxide and a galactomannan such as guar. The compositions are particularly well suited for ophthalmic applications such as contact lens disinfection and rewetting. Methods for the treatment of dry eye using the compositions of the present invention are also contemplated.

Abstract: The present invention relates to processes for purifying guar comprising combining borate and guar in an aqueous solution and treating the aqueous solution with an organic solvent to induce precipitation of purified guar. Another embodiment of the present invention is directed to ophthalmic formulations comprising purified guar produced by the processes described.

Abstract: The present invention relates to artificial tear formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a cis-diol such as sorbitol that interferes with the cross-linking of galactomannan and borate. Optionally, the formulations are substantially free of divalent cations.

Abstract: A vehicle includes a first control configured to operate the vehicle from a first operator position facing a front of the vehicle and a second control configured to operate the vehicle from a second operator position facing a rear of the vehicle. The vehicle further includes a processor configured to monitor for an operator presence in the first operator position or the second operator position and receive a vehicle operating request, wherein the operator presence is monitored independent of receiving the vehicle operating request. The processor is further configured to enable either the first control or the second control and select a vehicle operating parameter associated with the vehicle operating request, wherein the vehicle operating parameter varies according to which control is enabled.